Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? - Wikidata - wikimedia - TriplyDB

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

http://www.wikidata.org/entity/Q28540537

about

Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal Legal highs: staying on top of the flood of novel psychoactive substances Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice NPS: Medical Consequences Associated with Their Intake Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.Spice-y Kidney Failure: A Case Report and Systematic Review of Acute Kidney Injury Attributable to the Use of Synthetic Cannabis.Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.Baths salts, spice, and related designer drugs: the science behind the headlines.High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS.Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project.Synthetic Cannabinoids: Use and Predictors in a Community Sample of Young Adults.Neuronal substrates and functional consequences of prenatal cannabis exposure.Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market.Screening new psychoactive substances in urban wastewater using high resolution mass spectrometry.Assessment of the Abuse Liability of Synthetic Cannabinoid Agonists JWH-030, JWH-175, and JWH-176.Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific ma The Changing Face of Recreational Drug Use.Screening Medications for the Treatment of Cannabis Use Disorder.Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.Acute kidney injury associated with smoking synthetic cannabinoid.Toxicology and management of novel psychoactive drugs.Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018.Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development.What Can a Urine Drug Screening Immunoassay Really Tell Us?Synthetic Cannabinoids Use in Elderly Patients.Synthetic Pot: Not Your Grandfather's Marijuana.Mechanisms contributing to cognitive deficits in cannabis users.Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service.Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid.1-Adamantylamine a simple urine marker for screening for third generation adamantyl-type synthetic cannabinoids by ultra-performance liquid chromatography tandem mass spectrometry.Synthetic cannabinoid induced acute respiratory depression: Case series and literature review.Rhabdomyolysis and Acute Kidney Injury Requiring Dialysis as a Result of Concomitant Use of Atypical Neuroleptics and Synthetic Cannabinoids.Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice.Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'.Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.Cannabis, cannabinoids, and health.

P2860

Q26748662-31A14B54-37F9-47D5-AAC0-3ABB82320FCB Q26799231-2C957579-1666-44B2-8CE8-4983E9089D99 Q27312372-35B96CEB-80EF-45EC-B662-1E4DA9CDF3D7 Q28276182-DF3A39D7-930E-4389-AE11-826D0882C479 Q28554883-516D6A4B-7E44-4335-A6CC-763A0946FCEC Q30251771-1E324B77-2247-4710-A43C-AA47C9E8906F Q33655795-8456558A-D39D-4AEF-A2C4-BDA704966208 Q34167511-C2A9F932-B30E-4A34-A292-B16D57271840 Q34491601-A840A603-CBCE-4495-985E-A1422C2417F2 Q34493135-67A42C74-2FE3-4DA5-94D8-696D3902F27E Q34540515-89E4C797-F117-4848-BD26-1029DB2BCA36 Q35185931-1AF6AB0C-B250-4039-B05C-62A20E9A4D02 Q35694094-4A1AFCC5-AA82-49B3-80D6-57D46B04FAAB Q35836423-D0A0DB28-277D-4E34-AB66-6F3E68B2EA16 Q35991838-11AC24D9-2E00-46E1-A2E5-88F3EBBE7EA1 Q36218416-7D093EC6-7DE8-4C9C-94DA-2EE3852629DB Q36385137-7CA78360-7116-4061-B92E-311E41747644 Q37078847-49A4A580-ED71-4594-B42E-954244F39EA5 Q37187618-C3493ABC-B2FE-49DA-932D-AEFA2746CD26 Q37637031-F5AE771C-143D-48E2-B8F2-FA07047CD9C9 Q38236657-3AD001D1-BAFB-4FD2-8902-71A387541CD5 Q38254814-ADB5F981-6373-483F-B27F-A7D4BEB98DF0 Q38383364-BB36EE00-8481-46AC-A980-40382D20CBD0 Q38429080-4BB03BA0-06DE-4708-85C6-A03A898E461C Q38444921-42DC04D6-7135-4647-8416-934DEB51278D Q38792949-758E357F-8010-4382-B064-409DBEE3BB96 Q39120303-7BF1312D-2171-4F4F-9FE4-6FF8B3D21A36 Q39245794-49AEB4DD-55F4-4DAE-8CC4-60B4C191C417 Q39556033-696439CB-66F9-45C4-82C7-E6EB3C3CECE8 Q39841753-53792B33-2C8C-42E4-A5AA-CBA05584849E Q40054798-372D5255-9265-4465-ABAF-8B1C873CF1F8 Q40102790-141FE7EE-5878-403C-B1DA-10A8B255FE6E Q40126502-7511B04B-3CE7-407B-9615-77B2C92A14A7 Q41288789-A228548E-ED19-4FA8-BEA7-6767F33B0C3C Q41870686-7E31B307-5D37-473E-AD93-1BFAAD4EAF5C Q42581822-8A8B1F30-F14C-4C3C-AFAB-25E4CD49C221 Q42633075-35CE119F-8F51-4874-8CD0-9FE22E49074E Q42751396-289A97CE-5D80-497C-A42B-F0C91EE869DD Q45073154-529F2129-C956-4AB8-A389-4B1897E04E60 Q47139391-955B04C2-1942-4208-9C22-648DE42D6F0D

P2860

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

http://www.wikidata.org/entity/Q28540537

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Distinct pharmacology and meta ...... m underlying greater toxicity?

@ast

Distinct pharmacology and meta ...... m underlying greater toxicity?

@en

Distinct pharmacology and meta ...... m underlying greater toxicity?

@nl

type

label

Distinct pharmacology and meta ...... m underlying greater toxicity?

@ast

Distinct pharmacology and meta ...... m underlying greater toxicity?

@en

Distinct pharmacology and meta ...... m underlying greater toxicity?

@nl

prefLabel

Distinct pharmacology and meta ...... m underlying greater toxicity?

@ast

Distinct pharmacology and meta ...... m underlying greater toxicity?

@en

Distinct pharmacology and meta ...... m underlying greater toxicity?

@nl

P1433

Q28540537-A309FB83-EBAB-46D4-9564-F8D9A586AF86

P1476

Q28540537-457D96FF-52E8-497E-901A-B9A8C58CD3C6

P2093

Q28540537-1A884F9A-A001-4804-8AD1-04D9FB3A34CC

Q28540537-668B11C8-8835-4884-928C-42DD75961B90

Q28540537-CF2B093E-79F8-4DEA-8C93-22C1ECC19A5E

Q28540537-DF92011A-F731-4E1D-A316-A43093800DBD

P2860

Q28540537-00EC16AE-476A-43B1-AD7E-CA9F02E9C485

Q28540537-07BCAE25-57C8-449D-9F34-F418C030D6AB

Q28540537-0AB610EB-DF56-4360-8F65-C2ACBE7F16FD

Q28540537-0E657A18-47E6-4097-B2A8-F553CF81EA95

Q28540537-0EA148E6-FE11-4777-B4CB-1F1D1D7D7C10

Q28540537-0FBF2BC2-B16B-40FC-8675-FB8113070E90

Q28540537-103F99B4-1336-4B93-8FC4-4F2742FB9407

Q28540537-144F2203-304A-4392-9F49-366E4284AD8F

Q28540537-156CD301-694B-477C-A05F-9255BDE000B8

Q28540537-15C3FFD2-6796-4819-8268-F24009F5F5D8

P304

Q28540537-EED55051-FF63-40DF-B1AA-B705498662EF

P31

Q28540537-1DC0434B-EFAD-4BDB-BE34-80B062AA043D

P3181

Q28540537-240390B4-8AAB-4A5A-8DD4-410302F57212

P356

Q28540537-D32C6341-80F3-4F0E-AEC1-55280E263D2E

P407

Q28540537-9809ECFB-9925-4A1C-BDDA-A443F32C4C91

P433

Q28540537-FAE89B96-47E9-4D3A-888D-60B173BFB53E

P478

Q28540537-83717D8B-D6C1-45A1-B3BF-D34EAB789225

P577

Q28540537-68A28032-E040-436E-9D36-02516CAE9F97

P698

Q28540537-6DA992DE-8846-4B7E-9E87-B12D6A258A04

P921

Q28540537-485282E0-084D-4A23-A25B-D26CF84ACD63

Q28540537-AB8DEAB7-5724-46B9-8144-BD46C55318DB

Q28540537-ED42223E-CC8F-4DEF-A577-17F1FAC9A80F

P932

Q28540537-1448F573-8E43-476A-A807-0E102C5AB8E2

P3181

P356

J.LFS.2013.09.017

P1433

P1476

Distinct pharmacology and meta ...... m underlying greater toxicity?

@en

P2093

Anna Radominska-Pandya

http://www.w3.org/2001/XMLSchema#string

Jeffery H Moran

http://www.w3.org/2001/XMLSchema#string

Paul L Prather

http://www.w3.org/2001/XMLSchema#string

William E Fantegrossi

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity

Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats

Beyond THC: The New Generation of Cannabinoid Designer Drugs

The behavioral pharmacology of hallucinogens

Withdrawal phenomena and dependence syndrome after the consumption of "spice gold"

Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids

Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding

International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology

In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist

Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity

P304

45-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1033119

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.LFS.2013.09.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24084047

http://www.w3.org/2001/XMLSchema#string

P921

tetrahydrocannabinol

P932

3945037

http://www.w3.org/2001/XMLSchema#string